Thelansis

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy (CIPN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient s...

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook Thelansis’s “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy (CIPN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview Chemotherapy-induced peripheral neuropathy (CIPN) stands out as a prevalent adverse effect triggered by antineoplastic medications, with its occurrence ranging from 19% to over 85%. It primarily manifests as sensory nerve damage, accompanied by varying degrees and durations of motor and autonomic alt...

  Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common side effects caused by antineoplastic agents, with a prevalence ranging from 19% to over 85%. CIPN is predominantly sensory neuropathy accompanied by motor and autonomic changes of varying intensity and duration. Because of its high prevalence among cancer patients, CIPN constitutes a significant problem for both cancer patients and survivors and their health care providers, mainly because, at the moment, there is no single effective method of preventing CIPN. Central sensitization plays a role in pain, particularly in neuropathic pain. The literature suggested the involvement of a wide array of neurons, ion channels, signaling pathways, molecules, and non-neuronal cells in central sensitization. Damage to peripheral nerves (particularly C-fibers) causes spontaneous activity, which alters secondary order neurons in the spinal dorsal horn and results in hyper-excitability via various molecular changes. ...